Loading
A phase 3 trial of Nivolumab, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% is a phase 3 interventional study registered as NCT06561386 by Bristol-Myers Squibb, with 1000 participants planned, started 2024-10-07 and due to reach its primary completion in 2030-07-30. Interventions recorded: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Pembrolizumab.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.